-Yasuo Yoshioka Researcher Activity Profile

Research Author Detailed Information 

Yasuo Yoshioka Publication Rate By Year

Yasuo Yoshioka has published 9 paper(s) in 2007, 5 paper(s) in 2008, for a total of 14 research publications in total.

Yasuo Y Yoshioka Author Information

LAST NAME: yoshioka

FIRST NAME: yasuo

INITIALS: Y

AFFILIATION:

Papers

Yasuo Yoshioka's Publication Record

1. Novel correction methods as alternatives for the six-dimensional correction in CyberKnife treatment. Year Published: 2007
Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita 565-0871, Japan. suzuki@radonc.med.osaka-u.ac.jp
2. TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection. Year Published: 2007
Department of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6, Yamadaoka, Suita, Osaka 565-0871, Japan.
3. Efficient generation of antigen-specific cellular immunity by vaccination with poly(gamma-glutamic acid) nanoparticles entrapping endoplasmic reticulum-targeted peptides. Year Published: 2007
Department of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
4. Improved cytosolic translocation and tumor-killing activity of Tat-shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2 peptide. Year Published: 2007
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
5. Prostate Risk Index (PRIX) as a new method of risk classification for clinically localized prostate cancer. Year Published: 2007
Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. yoshioka@radonc.med.osaka-u.ac.jp
6. Improved cytosolic translocation and tumor-killing activity of Tat-shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2 peptide. Year Published: 2007
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
7. Efficient generation of antigen-specific cellular immunity by vaccination with poly(gamma-glutamic acid) nanoparticles entrapping endoplasmic reticulum-targeted peptides. Year Published: 2007
Department of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
8. Novel correction methods as alternatives for the six-dimensional correction in CyberKnife treatment. Year Published: 2007
Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita 565-0871, Japan. suzuki@radonc.med.osaka-u.ac.jp
9. Development of amphiphilic gamma-PGA-nanoparticle based tumor vaccine: potential of the nanoparticulate cytosolic protein delivery carrier. Year Published: 2008
Department of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
10. Prostate Risk Index (PRIX) as a new method of risk classification for clinically localized prostate cancer. Year Published: 2007
Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. yoshioka@radonc.med.osaka-u.ac.jp
11. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. Year Published: 2008
National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
12. Development of amphiphilic gamma-PGA-nanoparticle based tumor vaccine: potential of the nanoparticulate cytosolic protein delivery carrier. Year Published: 2008
Department of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
13. Preparation of a tat-related transporter Peptide for carrying the adenovirus vector into cells. Year Published: 2008
Life Science Center, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Minatojima, Chuo-ku, Kobe 650-8586, Japan. kawasaki@pharm.kobegakuin.ac.jp.
14. Development of PEGylated adenovirus vector with targeting ligand. Year Published: 2008
Department of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.